Skip to Content

Xyntha Approval History

  • FDA approved: Yes (First approved February 21st, 2008)
  • Brand name: Xyntha
  • Generic name: antihemophilic factor (recombinant), plasma/albumin free
  • Company: Wyeth Pharmaceuticals Inc.
  • Treatment for: Hemophilia A

Xyntha (Antihemophilic Factor (Recombinant) Plasma/Albumin Free) is a genetically engineered version of factor VIII, a protein essential for the clotting of blood. Xyntha is indicated for the control and prevention of bleeding episodes and for surgical prophylaxis in patients with hemophilia A.

Development History and FDA Approval Process for Xyntha

Feb 21, 2008Approval FDA Licenses Xyntha, a New Hemophilia Treatment

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.